Fewer than three out of five women with cervical cancer received guideline-based care, a new study finds. For black and Hispanic women, it’s just over half, which could help explain why cervical cancer outcomes tend to be worse for these women.
It’s well known that women with certain hereditary genetic mutations, particularly BRCA1 and BRCA2, have an increased risk of breast cancer. But in recent years, researchers have discovered a link between some of those same genetic mutations – along with a handful of others – and aggressive prostate cancer.
A new study from researchers at the University of Michigan Comprehensive Cancer Center identifies a protein in that microenvironment that promotes the spread of breast cancer cells. It’s part of a well-known family of receptors for which promising inhibitors are being developed.
Nearly one-third of early stage breast cancer patients overestimate their risk of cancer recurrence — believing it to be more than double their actual risk. And that overestimation is affecting their quality of life, according to two recent studies. The good news? A more nuanced approach to doctor-patient communication may help improve patients’ understanding.
Physicians often fail to recommend genetic testing for breast cancer patients at high risk for mutations associated with ovarian and other cancers, according to a new study.
After a decade of using a novel approach to select patients for laryngeal cancer treatment, researchers are reporting "exceptional" survival rates nearing 80 percent, even for the most advanced patients.
Cervical cancer is a preventable disease if detected on time, but it remains one of the leading causes of cancer deaths among women in Latin America, particularly women of poor and indigenous communities.
Nearly half of women treated for early stage breast cancer reported at least one side effect from their treatment that was severe or very severe, a new study finds.
A protein thought to fuel pancreatic cancer development plays a much more complicated role, a new study finds. PDX1 is critical for cancer growth, but blocking it may lead to more aggressive tumors.
Recognizing a critical need to improve national vaccination rates for the human papillomavirus, the University of Michigan Comprehensive Cancer Center has again united with each of the 69 National Cancer Institute-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention.